The Fall and Second Chance of Braskem: What the IG4 Capital Takeover Tells Us About the Bioplastics Industry

Latin America’s largest petrochemical company has just changed hands — not through a traditional acquisition, but through a labyrinthine debt-for-equity conversion that is itself a testament to how deeply troubled the company’s history has been. On March 7, 2026, Brazil’s antitrust authority CADE approved private equity firm IG4 Capital’s acquisition of a controlling stake in Braskem SA from conglomerate Novonor, ending a saga that began with one of the largest corruption scandals in Latin American history.

The story of Braskem is also, in its own way, a story about bioplastics — because Braskem happens to be the world’s largest producer of bio-based polyethylene and a company that has staked part of its identity on being green. So what does this corporate near-collapse mean for the bioplastics sector?

From Odebrecht Crown Jewel to Distressed Asset

To understand why Braskem is in its current predicament, you have to go back to its former parent: Odebrecht, one of Brazil’s most powerful conglomerates, renamed Novonor in 2020. Odebrecht was at the center of Lava Jato — Operation Car Wash — the largest corruption investigation in Latin American history, implicating a bribery network spanning 12 countries and resulting in a $3.5 billion settlement with US, Brazilian, and Swiss authorities. In June 2019, Odebrecht filed the largest judicial recovery request in Latin American history, carrying debts of R$98.5 billion.

Braskem, founded in 2002, was the empire’s crown jewel — the largest resin producer in the Americas, employing more than 8,500 people and generating nearly $14 billion in annual sales. It remained largely intact even as the parent company collapsed, but the uncertainty over who would ultimately control it created a decade-long governance vacuum that paralyzed decision-making and discouraged investment.

The corporate structure that emerged from Odebrecht’s implosion left Novonor holding 50.1% of Braskem’s voting shares — pledged as collateral against approximately R$20 billion in debt held by five major Brazilian banks (Itaú, Bradesco, Santander, Banco do Brasil, and the national development bank BNDES). Petrobras, the state-owned oil company, held the remaining 47% of voting shares and was simultaneously Braskem’s largest feedstock supplier — an obvious conflict of interest.

One analyst described the resulting structure as “a basket case of corporate governance.”

Three Crises Stacked on Top of Each Other

Beyond its dysfunctional ownership structure, Braskem has faced three overlapping crises that have hammered its finances and reputation.

The Alagoas Environmental Disaster. Beginning in 2018, sinkholes began opening in five neighborhoods of Maceió, the capital of the northeastern state of Alagoas. The cause: decades of rock salt mining by Braskem, which had dissolved underground salt caverns to produce brine for its chlor-alkali operations. Around 60,000 residents were forced to abandon their homes. Braskem ended mining operations in 2019, but by 2026 has spent over $3.6 billion in compensation, relocation support, and remediation — with the final cost still uncertain and further legal proceedings underway. The environmental liability has been cited as a key factor deterring multiple potential buyers over the years.

The Global Petrochemical Downturn. Since 2022, the global petrochemical industry has been mired in what industry observers are calling one of its longest and deepest cyclical downturns. Braskem has been hit especially hard. Its operating margin turned negative (-2.09%), with a net margin of -7.11% and losses of nearly R$39.1 billion in market value over five years. In the second quarter of 2025 alone, recurring EBITDA collapsed 77% year-on-year to just $74 million, while net leverage soared to 10.6 times EBITDA. The company also faces a separate restructuring of over $2 billion in debt from its Mexican joint venture Braskem Idesa.

The Ownership Limbo. For years, potential buyers circled Braskem and walked away — LyondellBasell in 2019, Abu Dhabi’s ADNOC (which had offered R$10.5 billion before pulling out in May 2024), Unipar, J&F, and various Brazilian investors. Each departure deepened the uncertainty, depressed the share price further, and made it harder to attract management talent and secure financing for strategic decisions.

Enter IG4 Capital: Distressed Assets Are Their Business

The deal that finally cleared regulatory approval is unusual by any standard. IG4 Capital, a Brazilian-based private equity firm that describes itself as specializing in “special situations and market dislocations,” did not purchase Braskem shares directly. Instead, it acquired approximately R$20 billion ($3.5 billion) in Novonor debt from the consortium of creditor banks — and will convert that debt into equity, giving it control of Novonor’s 50.1% voting stake through a vehicle called Shine I FIDC. This structure allowed IG4 to assume control without a traditional share purchase, and without Novonor ever receiving cash.

CADE approved the transaction without restrictions on March 7, 2026, though the decision still has a 15-day window during which it can be appealed by the agency’s administrative tribunal. Novonor will retain a residual 4% stake. IG4 will share control with Petrobras — but only once a new shareholders’ agreement is negotiated, which has not yet happened.

The approval came at an almost comically precarious moment: on the same day CADE announced its decision, Brazilian financial newspaper Valor Econômico reported that IG4 had been considering abandoning the negotiations entirely due to regulatory delays. Petrobras’s CEO stated publicly that the decision could still be overturned, and that the company would require a new shareholder pact before considering any capital injection. According to the same reporting, Braskem could face bankruptcy protection within two to three months if conditions do not improve.

IG4 Capital’s website describes its target companies as those “facing challenges that could greatly benefit from a hands-on, seasoned team of executives.” Braskem certainly qualifies. The challenge ahead is formidable: stabilize a balance sheet carrying leverage at 14.7 times EBITDA, negotiate with Petrobras on governance, resolve the Alagoas liabilities, restructure the Mexican joint venture, and eventually exit the investment at a profit. Analysts estimate this turnaround could take five years — if it succeeds at all.

What About Bioplastics?

Here is where the story becomes relevant to a broader audience in the sustainable materials sector.

Braskem is not just a petrochemical giant in distress. It is also the world’s leading producer of bio-based polyethylene (PE) and a pioneer in the commercial-scale production of plastics from renewable feedstocks. Its “I’m Green” brand, launched in 2010, produces bio-based HDPE and LDPE from sugarcane ethanol at its plant in Triunfo, Rio Grande do Sul, Brazil — where it expanded capacity from 200,000 to 260,000 tons per year in 2023 at a cost of $87 million. Each ton of bio-based PE produced avoids approximately 5 kg of CO₂ equivalent compared to fossil-based alternatives, according to third-party lifecycle assessments. The company supplies bio-based materials to over 250 brands in more than 30 countries, including partners like Allbirds, Johnson & Johnson, Natura, and Tetra Pak.

Sales volumes for biobased PE reached 191,000 tons in 2024, up 23% from the prior year — a bright spot in an otherwise bleak financial picture. Braskem has stated its ambition to reach 1 million tons of annual bio-based and bio-attributed production capacity by 2030, and has invested in a Renewable Innovation Center in Lexington, Massachusetts, to develop next-generation feedstock conversion technologies.

Does Braskem’s financial crisis mean the bioplastics strategy has failed? Not exactly.

The bio-based business is genuinely growing, and Braskem’s struggles are almost entirely due to the problems described above: the Alagoas disaster, the petrochemical cycle, and the Novonor governance crisis. The sugarcane-to-PE business remains commercially viable and strategically differentiated. Its products carry certified negative carbon footprints and are fully recyclable within existing PE waste streams — a rare combination that makes them attractive to brand owners navigating packaging regulations in Europe and elsewhere.

However, the financial distress does illustrate a structural challenge that faces any bioplastics producer embedded within a larger petrochemical operation: when conventional resin margins collapse in a downturn cycle, the parent company’s cash flows deteriorate sharply, putting investment in bio-based capacity expansion at risk. Bioplastics volumes are still a small share of Braskem’s overall output — 191,000 tons of bio-PE in a company producing millions of tons of conventional resins. When the company is burning cash at the corporate level, even profitable niche segments can suffer from capital rationing.

The broader lesson here is one of financial architecture. Braskem’s bioplastics ambitions were genuine and commercially real, but they were attached to a deeply indebted holding company with unresolved environmental liabilities and dysfunctional governance. The “green” strategy could not insulate the company from the weight of those legacy problems.

What Happens Next?

IG4 Capital inherits a company that is simultaneously a near-bankrupt petrochemical producer and the world’s most established commercial biopolymer platform. The two don’t easily coexist under financial duress.

The most likely near-term priority for IG4 will be financial stabilization: negotiating a new shareholder agreement with Petrobras, restructuring Braskem Idesa, and finding a path to reducing leverage before the company runs out of liquidity. Whether that process preserves or undermines the bioplastics investment roadmap remains to be seen.

For the bioplastics sector more broadly, the Braskem saga is a cautionary tale about the importance of corporate governance, balance sheet health, and ownership clarity. Even a world-leading position in bio-based materials is not enough to protect a company from the consequences of systemic mismanagement elsewhere in its structure.

If IG4 succeeds in stabilizing Braskem and eventually executing on the 2030 biopolymers growth strategy, this acquisition could mark a turning point: the moment a distressed-asset specialist rescued the world’s most important bioplastics platform from the wreckage of a corruption scandal. If it fails, the consequences will extend well beyond Brazil’s petrochemical sector.

Sources: Reuters, Bloomberg, CADE regulatory filings, Braskem SA annual reports and press releases, Valor Econômico, Agência Brasil, Plastics News, Packaging Dive, The Rio Times, NeoFeed.